Clinical trials: Chikungunya Virus Infection
Chikungunya Virus Infection
VLA1553-403 Pregnancy Surveillance Study
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last…
- Trial name
- NCT07414524
- Testing
- Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH
- Where
- 3 sites in Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Chikungunya Virus Detection in Semen
Chikungunya is an arboviral disease transmitted by Aedes mosquitoes, present in intertropical zones and Europe. In August 2024, autochthonous cases appeared on Réunion, followed by a large epidemic.
- Trial name
- CHIKSPERM (NCT06983548)
- Testing
- semen, blood and urine tests
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Chikungunya, Chikungunya Fever
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60…
- Conditions
- Chikungunya, Chikungunya Fever, Chikungunya Virus Infection, Chikungunya Virus Infections
- Trial name
- NCT07394426
- Testing
- PepGNP-ChikV
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Chikungunya Virus
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
- Trial name
- NCT05349617
- Testing
- CHIKV VLP/adjuvant
- Where
- 10 sites in United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy Adult, Healthy Adolescents
Evaluation of IXCHIQ® Vaccine Immunogenicity
The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents.
- Trial name
- IMUNO-CHIQ (NCT07846293)
- Testing
- IXCHIQ vaccine
- Where
- Brazil
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mauro Martins Teixeira
Chikungunya
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed.
- Trial name
- NCT03101111
- Testing
- MV-CHIK, MMR-vaccine
- Where
- Puerto Rico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Fever, Dengue
Cohort of Patients Infected by an Arbovirus
There are hundred of arbovirus which have been shown to cause disease in humans. Their most common clinical symptoms are algo-eruptive (dengue, chikungunya, zika), hemorrhagic fever (dengue, yellow fever, Crimean-Congo…
- Conditions
- Fever, Dengue, Chikungunya, Zika Virus
- Trial name
- CARBO (NCT01099852)
- Testing
- biological sample collection, Quality of life Questionnaire EuroQol®, Health Assessment Questionnaire - MDHAQ and RAPID3
- Where
- 8 sites in France, French Guiana and 3 more
- Volunteers
- 1,377 people
- Sponsor
- University Hospital Center of Martinique
Chikungunya
Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Reunion Island was struck by a severe Chikungunya outbreak in 2005-2006. Three hundred and seven Chikungunya patients were evaluated by 4 rheumatologists 2 months after the initial infection (RHUMATOCHIK study).
- Trial name
- ChikRhuma15 (NCT04838574)
- Testing
- 15 years Follow-up group
- Where
- 3 sites in Reunion
- Volunteers
- 152 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Early Chikungunya Arthritis
Efficacy of Starting Methotrexate Early in Chikungunya Arthritis
This is a single center, prospective, randomized controlled open label trial with a one sided cross over design to compare the efficacy of initiating Methotrexate(Mtx) in early post Chikungunya induced arthritis (4-12 weeks after…
- Trial name
- NCT03058471
- Testing
- Methotrexate, NSAID, Steroids
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Viral Vaccines, Chikungunya Fever
Chikungunya Virus Vaccine Trial in Healthy Adults
Background: Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death.
- Conditions
- Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
- Trial name
- NCT01489358
- Testing
- VRC-CHKVLP059-00-VP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Phase 1 Study of SAR440894 vs Placebo
A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at multiple sites.
- Trial name
- NCT04441905
- Testing
- SAR440894
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Chikungunya, Arthritis
Chikungunya Arthritis in the Americas
Chikungunya is a mosquito-borne viral illness that leads to chronic joint pain in approximately one half of patients. The mechanisms leading to long term arthritis in humans has not been well established.
- Trial name
- NCT02463968
- Testing
- Venipuncture for blood draw, Arthrocentesis for synovial fluid draw
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- George Washington University
Chikungunya Virus
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], aluminum hydroxide adjuvanted).
- Trial name
- CHIKV VLP (NCT05065983)
- Testing
- CHIKV VLP, adjuvanted
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Exanthema, Dengue Fever
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an…
- Conditions
- Exanthema, Dengue Fever, Chikungunya, Measles
- Trial name
- CRIUS (NCT07112846)
- Volunteers
- 830 people
- Sponsor
- Hospital Israelita Albert Einstein
Chikungunya
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
This study has a Phase II with part A and part B and a Phase III with part C. This Adaptive seamless design will prospectively include planned modifications and incorporate both dose selection (parts A and B) and confirmation of…
- Trial name
- IVICHIK001 (NCT04566484)
- Testing
- BBV87 Chikungunya vaccine, Normal Saline
- Where
- 7 sites in Colombia, Costa Rica and 3 more
- Volunteers
- 3,210 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge